Dysangco, Andrew T.Pierce, Tamra M.Bravata, Dawn M.2023-10-032023-10-032022-08-26Dysangco AT, Pierce TM, Bravata DM. Risk of antibiotics associated with Clostridioides difficile infection: Antibiotic stewardship in action. Antimicrob Steward Healthc Epidemiol. 2022;2(1):e146. Published 2022 Aug 26. doi:10.1017/ash.2022.286https://hdl.handle.net/1805/35958We examined risk associated with antibiotics used for Clostridioides difficile infection (CDI) at a single site from 2018 through 2020. Overall, 78 patients had nonrecurrent infections. Among inpatient antibiotics, intravenous meropenem had the highest CDI rate (3.56 per 1,000 days of therapy; n = 2 cases). Among outpatient antibiotics, metronidazole had the highest rate (0.071 per 1,000 pills dispensed; n = 3 cases).en-USAttribution 4.0 InternationalClostridioides difficile infection (CDI)Intravenous meropenemMetronidazoleArticle